![]() ![]() Graphic AbstractĬontrast agents (CAs) play an essential role in obtaining accurate diagnosis results for the current magnetic resonance imaging (MRI) technology. Therefore, Linear pDHPMA-mPEG-Ppa-PROXYL could be a potential candidate as a substitute of metal-based MRI CAs for clinical application. Additionally, it was demonstrated to have great biosafety, hemocompatibility and biocompatibility. Thus, Linear pDHPMA-mPEG-Ppa-PROXYL could provide a clearly detectable MRI enhancement at the tumor site of mice via the T1WI SE sequence conventionally used in clinical Gd 3+-based contrast agents, although it cannot be compared with DTPA-Gd in the longitudinal relaxivity and the continuous enhancement time at the tumor site of mice. 8 h and great accumulation of the mCA was realized in the tumor site due to its passive targeting ability to tumors. The blood retention time of PROXYL from the prepared mCA in vivo was up to ca. Its longitudinal relaxivity ( r 1 = 0.93 mM − 1 s − 1) was the highest compared to reported nitroxides-based mCAs. A high content of PROXYL up to 0.111 mmol/g in Linear pDHPMA-mPEG-Ppa-PROXYL was achieved and a stable nano-sized self-assembled aggregate in an aqueous environment (ca. Herein, a water-soluble biodegradable nitroxides-based mCA (Linear pDHPMA-mPEG-Ppa-PROXYL) was prepared via covalent conjugation of a nitroxides (2,2,5,5-tetramethyl-1-pyrrolidinyl- N-oxyl, PROXYL) onto an enzyme-sensitive linear di-block poly (pDHPMA). In addition, these mCAs still raise the concerns over biocompatibility and biodegradability due to the presence of macromolecules in these mCAs. Amphiphilic nanostructures in these mCAs are not stable enough for highly efficient protection of nitroxides and do not have adequate molecular flexibility for full contact of the paramagnetic center with the peripheral water molecules. These mCAs do not possess a high nitroxides content sufficient for a cumulative effect. To learn more about Bracco Imaging, visit of nitroxides has been an effective strategy to improve low relaxivities and poor in vivo stability, however, nitroxides-based metal-free magnetic resonance imaging (MRI) macromolecular contrast agents (mCAs) are still under-performed. Bracco Group global revenues were 1.4 billion Euros in 2020. R&D activities are located in four centers based in Italy, Switzerland, the United Kingdom, and the United States. Bracco Imaging has a well-skilled and innovative Research and Development (R&D) organization with an efficient process-oriented approach and track record in the diagnostic imaging industry. ![]() Bracco Imaging has approximately 3,600 employees and operates in more than 100 markets globally. The Bracco Imaging portfolio includes products and solutions for all key diagnostic imaging modalities: X-ray imaging, magnetic resonance imaging (MRI), Contrast Enhanced Ultrasound (CEUS), and Nuclear Medicine through radioactive tracers and novel PET imaging agents. Headquartered in Milan, Italy, Bracco Imaging's purpose is to improve people's lives by shaping the future of prevention and precision diagnostic imaging. ("Bracco Imaging"), part of the Bracco Group, is an innovative world leader delivering end-to-end products and solutions through its comprehensive portfolio across diagnostic imaging modalities. ![]()
0 Comments
Leave a Reply. |